Citadel Advisors
SWTX

Citadel Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Citadel Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-573,700
Closed -$27M – 14065
2025
Q2 		$27M Buy
573,700
+178,200
+45% +$7.93M ﹤0.01% 1807
2025
Q1 		$17.5M Buy
395,500
+392,100
+11,532% +$18M ﹤0.01% 2191
2024
Q4 		$123K Sell
3,400
-5,400
-61% -$189K ﹤0.01% 11149
2024
Q3 		$282K Buy
8,800
+5,700
+184% +$213K ﹤0.01% 9463
2024
Q2 		$117K Sell
3,100
-41,500
-93% -$1.75M ﹤0.01% 10694
2024
Q1 		$2.2M Buy
44,600
+9,800
+28% +$453K ﹤0.01% 5343
2023
Q4 		$1.27M Buy
34,800
+32,100
+1,189% +$838K ﹤0.01% 6215
2023
Q3 		$62.4K Sell
2,700
-6,200
-70% -$170K ﹤0.01% 11475
2023
Q2 		$233K Buy
8,900
+4,000
+82% +$105K ﹤0.01% 9548
2023
Q1 		$126K Sell
4,900
-41,600
-89% -$1.22M ﹤0.01% 10921
2022
Q4 		$1.21M Sell
46,500
-33,800
-42% -$833K ﹤0.01% 6445
2022
Q3 		$2.29M Buy
80,300
+44,400
+124% +$1.27M ﹤0.01% 5330
2022
Q2 		$884K Sell
35,900
-18,500
-34% -$677K ﹤0.01% 7306
2022
Q1 		$3.07M Buy
+54,400
New +$3.11M ﹤0.01% 5119

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's SWTX Position: Q3 2025 in Review

Citadel Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 74,505 shares — an estimated $3.5M sold.

Citadel Advisors first reported a position in SWTX in Q3 2019 and held it in 24 quarters. The position peaked at $66.9M in Q2 2021. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Citadel Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 74,505 SpringWorks Therapeutics shares in Q3 2025, an estimated $3.5M.
  • Citadel Advisors first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 24 quarters.
  • Citadel Advisors's SpringWorks Therapeutics position peaked at $66.9M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.